Current progress, challenges and future prospects of indazoles as protein kinase inhibitors for the treatment of cancer
Open Access
- 20 July 2021
- journal article
- review article
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 11 (41) , 25228-25257
Abstract
The indazole core is an interesting pharmacophore due to its applications in medicinal chemistry. In the past few years, this moiety has been used for the synthesis of kinase inhibitors. Many researchers have demonstrated the use of indazole derivatives as specific kinase inhibitors, including tyrosine kinase and serine/threonine kinases. A number of anticancer drugs with an indazole core are commercially available, e.g. axitinib, linifanib, niraparib, and pazopanib. Indazole derivatives are applied for the targeted treatment of lung, breast, colon, and prostate cancers. In this review, we compile the current development of indazole derivatives as kinase inhibitors and their application as anticancer agents in the past five years.Keywords
Funding Information
- Anusandhan National Research Foundation (CRG/2018/002159)
- Council of Scientific and Industrial Research, India (02(0310)/17/EMR-II)
This publication has 176 references indexed in Scilit:
- G protein-coupled receptor kinases: More than just kinases and not only for GPCRsPharmacology & Therapeutics, 2012
- Rho‐kinase/ROCK: A key regulator of the cytoskeleton and cell polarityCytoskeleton, 2010
- Cell Signaling by Receptor Tyrosine KinasesCell, 2010
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- The FGF family: biology, pathophysiology and therapyNature Reviews Drug Discovery, 2009
- How does the Schwann cell lineage form tumors in NF1?Glia, 2008
- Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibitionCellular Signalling, 2007
- The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismNature Reviews Genetics, 2006
- Exploiting the PI3K/AKT Pathway for Cancer Drug DiscoveryNature Reviews Drug Discovery, 2005
- Mutations of the BRAF gene in human cancerNature, 2002